Samarth Kulkarni is Chief Executive Officer of CRISPR Therapeutics AG. Currently has a direct ownership of 222,500 shares of CRSP, which is worth approximately $10.4 Million. The most recent transaction as insider was on Aug 08, 2024, when has been sold 100,000 shares (Common Shares) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 223K
6.91% 3M change
42.56% 12M change
Total Value Held $10.4 Million

Samarth Kulkarni Transaction History

Date Transaction Value Shares Traded Shares Held Form
Aug 08 2024
SELL
Bona fide gift
-
100,000 Reduced 31.01%
222,500 Common Shares
Apr 15 2024
SELL
Open market or private sale
$1,177,661 $60.14 p/Share
19,582 Reduced 8.6%
208,122 Common Shares
Apr 15 2024
BUY
Exercise of conversion of derivative security
$374,407 $19.12 p/Share
19,582 Added 7.92%
227,704 Common Shares
Mar 15 2024
SELL
Open market or private sale
$1,450,200 $72.51 p/Share
20,000 Reduced 8.77%
208,122 Common Shares
Mar 15 2024
BUY
Exercise of conversion of derivative security
$382,400 $19.12 p/Share
20,000 Added 8.06%
228,122 Common Shares
Mar 12 2024
SELL
Open market or private sale
$341,158 $74.44 p/Share
4,583 Reduced 2.15%
208,122 Common Shares
Mar 11 2024
SELL
Open market or private sale
$767,104 $78.26 p/Share
9,802 Reduced 4.59%
203,705 Common Shares
Mar 11 2024
BUY
Exercise of conversion of derivative security
-
9,000 Added 4.06%
212,705 Common Shares
Mar 10 2024
BUY
Exercise of conversion of derivative security
-
19,250 Added 8.27%
213,507 Common Shares
Feb 20 2024
SELL
Open market or private sale
$507,497 $79.67 p/Share
6,370 Reduced 3.18%
194,257 Common Shares
Feb 18 2024
BUY
Exercise of conversion of derivative security
-
13,250 Added 6.2%
200,627 Common Shares
Feb 15 2024
SELL
Open market or private sale
$1,617,600 $80.88 p/Share
20,000 Reduced 9.64%
187,377 Common Shares
Feb 15 2024
BUY
Exercise of conversion of derivative security
$382,400 $19.12 p/Share
20,000 Added 8.8%
207,377 Common Shares
Jan 29 2024
SELL
Open market or private sale
$3,040,000 $60.8 p/Share
50,000 Reduced 21.06%
187,377 Common Shares
Jan 29 2024
BUY
Exercise of conversion of derivative security
$956,000 $19.12 p/Share
50,000 Added 17.4%
237,377 Common Shares
Jan 16 2024
SELL
Open market or private sale
$1,250,000 $62.5 p/Share
20,000 Reduced 9.64%
187,377 Common Shares
Jan 16 2024
BUY
Exercise of conversion of derivative security
$382,400 $19.12 p/Share
20,000 Added 8.8%
207,377 Common Shares
May 30 2023
SELL
Open market or private sale
$1,628,250 $65.13 p/Share
25,000 Reduced 6.06%
387,377 Common Shares
May 30 2023
BUY
Exercise of conversion of derivative security
$478,000 $19.12 p/Share
25,000 Added 5.72%
412,377 Common Shares
Apr 25 2023
SELL
Open market or private sale
$1,274,500 $50.98 p/Share
25,000 Reduced 6.06%
387,377 Common Shares
Apr 25 2023
BUY
Exercise of conversion of derivative security
$478,000 $19.12 p/Share
25,000 Added 5.72%
412,377 Common Shares
Mar 29 2023
SELL
Open market or private sale
$1,114,250 $44.57 p/Share
25,000 Reduced 6.06%
387,377 Common Shares
Mar 29 2023
BUY
Exercise of conversion of derivative security
$478,000 $19.12 p/Share
25,000 Added 5.72%
412,377 Common Shares
Mar 13 2023
SELL
Payment of exercise price or tax liability
$408,169 $43.22 p/Share
9,444 Reduced 2.38%
387,377 Common Shares
Mar 11 2023
BUY
Exercise of conversion of derivative security
-
9,000 Added 2.25%
391,463 Common Shares

Also insider at

BDTX
Black Diamond Therapeutics, Inc. Healthcare
RPTX
Repare Therapeutics Inc. Healthcare
CNTA
Centessa Pharmaceuticals plc Healthcare
SK

Samarth Kulkarni

Chief Executive Officer
Boston, MA

Track Institutional and Insider Activities on CRSP

Follow CRISPR Therapeutics AG and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CRSP shares.

Notify only if

Insider Trading

Get notified when an Crispr Therapeutics Ag insider buys or sells CRSP shares.

Notify only if

News

Receive news related to CRISPR Therapeutics AG

Track Activities on CRSP